HOME >> MEDICINE >> NEWS
Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment
'"/>

Contact: Christine Cassiano, Amgen
805-447-4587
Porter Novelli
15-Nov-2005


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
(Date:7/29/2014)... Clara, CA (PRWEB) July 29, 2014 ... Valley Boomer Venture Summit concluded with the $10,000 prize ... of Bikanta. ( http://www.bikanta.com ) , The 11th Annual ... pairs investors with entrepreneurs who can bring innovative products ... , “We are pleased to have had such excellent ...
(Date:7/29/2014)... "Acceptance, Recognition, and Control (A.R.C.) Against Depression" was written ... other men to heed the call to self-help.. , Ray ... had no job, leaving Raymond with a mortgage payment he ... assistance, the emotional disturbance was so great that they put ... get to the root of his problems. , Raynond says, ...
(Date:7/29/2014)... Oconto Falls, WI (PRWEB) July 29, 2014 ... their third development project, The Cottages at MeadowLands Memory ... the growing population of those suffering from memory loss ... W.M. Enterprises, Inc., has approved the development of Oconto ... memory care. Cara Peterson, GM of The Cottages Investment ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tucson-based company ... an employer’s benefits package, or health and wellness program, ... balance while providing an effective way for employees to ... advantage of the program, employees specify the amount of ... Account. , An employer benefits from offering a 401(play)™ ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2
(Date:7/28/2014)... June 28 th , 2014 – Oncolab, the ... test, is making its AACC debut (booth #4051) at this ... a serum-based in vitro immunoassay, has been run for over ... the fight against cancer recurrence. Photo - ... cancer survivors in the US alone, the race is on ...
(Date:7/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: Portugal Pharmaceuticals and Healthcare ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 FREE ... economic growth last quarter has led us to ... As forecast previously, BMI expects Portugal,s ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
Cached News: